A three-month longitudinal randomized study was conducted in 400 exclusive heavy smokers with no intent to quit. They were randomly assigned to one of four conditions, with three receiving a Glas age-gated ENDS (tobacco flavored, menthol flavored or flavors) to use for 3 months. The control condition received the FDA authorized NJOY tobacco flavored ACE. Self-report survey data were collected at baseline and each follow-up site visit (month 1, 2, and 3). The primary objective for this study was to assess the APPH benefit, specifically cessation and past 30 days CPD reduction of 50% or greater after 3 months of use under the four conditions. Results showed that for participants with any reduction from baseline (i.e., 1-49% reduction, 50-99% reduction, and cessation) the population of menthol-flavored Glas users (Odds Ratio (OR) = 3.20) are estimated to benefit the most, followed by the flavored Glas condition users (OR = 1.68) and tobacco-flavored Glas users (1.10). Use of the Glas products reduced past 30 Day CPD ≥ 50% in 45 – 46 % of the participants compared to 48% for the NJOY ACE. 13 to 21% of the Glas product users completely quit smoking after 3 months compared to 11% for the NJOY ACE. Combining all cigarette reduction (1 to 100%), 79 to 92% of the Glas users benefited whereas only 77% of the NJOY users benefited. Overall, these findings suggest that the adult smokers benefitted more from the Glas ENDS than the NJOY ACE. The Glas ENDS are age-gated, the NJOY ACE is not. Since the reduction in CPD and cessation rates after use of the Glas ENDS were essentially equivalent to the NJOY control, and the Glas ENDS are age-gated, preventing any use by underage individuals, the Glas ENDS should be viewed as substantially superior in terms of benefit to adults as compared to risk to youth.